ReCode Therapeutics https://validator.w3.org/feed/docs/rss2.html ReCode Therapeutics to Participate in Upcoming Investor Conferences ReCode Therapeutics Announces First Participants Dosed in a Phase 1 Healthy Volunteer Clinical Study of Inhaled mRNA-Based Genetic Medicine, RCT2100, for the Treatment of Cystic Fibrosis ReCode Therapeutics Announces Additional Funding from the Cystic Fibrosis Foundation to Accelerate Development of Novel Gene Correction Therapeutics to Treat Cystic Fibrosis ReCode Therapeutics Initiates Enrollment of Phase 2 Clinical Trial of RCT2100 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis ReCode Therapeutics Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy for the Treatment of Primary Ciliary Dyskinesia Pipeline Senior/Executive Director, Translational Sciences & Nonclinical Operations ReCode Therapeutics to Participate in May Conferences Virtual Piper Sandler Lung Day Post-ATS American Thoracic Society: Respiratory Innovation Summit TIDES USA 2024 Capital One Biotech – Life Sciences Disruptors ASGCT Annual Meeting Wells Fargo Virtual Private Biotech Symposium ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT1100 for the Treatment of Primary Ciliary Dyskinesia Opt-out preferences ReCode Therapeutics to Participate in February Conferences Evercore ISI 2024 Emerging Biotech Conference William Blair Private Company Focus Conference Research Associate II, Bioanalytical Development (Contract) ReCode Therapeutics Receives U.S. FDA Orphan Drug Designation for RCT2100 for the Treatment of Cystic Fibrosis J.P. Morgan Healthcare Conference LNP Formulation & Process Development Summit ReCode Announces Two Key Additions to Scientific Advisory Board ReCode Therapeutics Presents Preclinical Data from its Cystic Fibrosis Program at the 2024 North American Cystic Fibrosis Conference (NACFC) in Boston ReCode Therapeutics Doses First Patient in Phase 1b Clinical Study of RCT2100 for the Treatment of Cystic Fibrosis Cystic Fibrosis Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis New Article Published in Science Highlights the Potential of ReCode Therapeutics’ Systemic Lung Delivery and CFTR Gene Correction Media Library News ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update Leadership Partnering Clinical Studies Primary Ciliary Dyskinesia ReCode Therapeutics Announces Appointment of Dean J. Mitchell as Chairman of its Board of Directors Patients Inhaled DNAI1 mRNA therapy for treatment of primary ciliary dyskinesia In vivo editing of lung stem cells for durable gene correction in mice RCT2100 rescue of cystic fibrosis (CF) transmembrane conductance regulator function in CF human bronchial epithelial cells and mucociliary clearance in CF ferrets 47th European Cystic Fibrosis Conference Scientist II, Chemistry Careers & Culture Science Our Purpose Powering the future of genetic medicines through superior delivery Events Morgan Stanley Healthcare Conference RNA Leaders USA Congress